Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPressUncategorized

σ1 Receptor modulation of opioid analgesia in the mouse.

Effects of sigma ligands on NMDA receptor function in the bulbectomy model of depression: A behavioural study in the rat.

Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell line.

Differential involvement of the sigma-1 receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse.

Beneficial effect of the sigma-1 receptor agonist PRE-084 against the spatial learning deficits in aged rats.

The interaction between neuroactive steroids and the sigma1 receptor function: Behavioral consequences and therapeutic opportunities.

Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina.

Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands.

The antidepressant-like effect induced by sigma-1 receptor agonists and neuroactive steroids in mice submitted to the forced swimming test.

Oxidative Damage Is the Earliest Event in Alzheimer Disease

1
2345678910111213141516171819202122232425262728293031323334353637383940
…4142434445…
4647
48
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top